Business Wire

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. In June 2025, Avanzanite entered into an exclusive agreement with Agios to commercialize and distribute PYRUKYND across the European Economic Area, the United Kingdom, and Switzerland. “The positive CHMP opinion for PYRUKYND represents a key step toward making th

Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journey from conversational AI to decision-based agentic supply chain orchestration. Unlike generic AI assistants that sit outside th

SLB (NYSE: SLB) today announced results for the third-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015948706/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2025Jun. 30, 2025Sept. 30, 2024SequentialYear-on-yearRevenue $8,928 $8,546 $9,159 4% -3% Income before taxes - GAAP basis $1,000 $1,285 $1,507 -22% -34% Income before taxes margin - GAAP basis 11.2% 15.0% 16.5% -383 bps -525 bps Net income attributable to SLB - GAAP basis $739 $1,014 $1,186 -27% -38% Diluted EPS - GAAP basis $0.50 $0.74 $0.83 -32% -40% Adjusted EBITDA* $2,061 $2,051 $2,343 0% -12% Adjusted EBITDA margin* 23.1% 24.0% 25.6% -92 bps -249 bps Pretax segment operating income* $1,626 $1,584 $1,902 3% -14% Pretax segment operating margin* 18.2% 18.5% 20.8% -32 bps -255 bps Net income attributable to SLB, excluding charges & credit

Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its selection, Dompé has been awarded a voucher granting a significantly shortened review timeline for marketing application and enhanced collaboration with the FDA. Dompé intends to apply the voucher for the Biologic License Application (BLA) for an intranasally administered formulation of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION). The intranasal administration of NGF is a novel approach, patented by Dompé, offering a non-invasive delivery method. “The CNPV represents a strategic lever to accelerate access to transformative therapies for patients with unmet medical needs as NAION,” said Sergio Dompé, Executive President at Dompé. “Building on our pioneering ach

(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infrastructure conference, held October 15-16 in Amsterdam. “Congratulations to this year’s Going Digital Award winners,” said Chris Bradshaw, chief sustainability and e

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its third quarter ended September 30, 2025. The call will be hosted on Thursday, November 6 at 8:30 a.m. Eastern Time by Bob Courteau, interim chief executive officer and chair, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the third quarter after the close of markets on Wednesday, November 5, 2025. CONFERENCE CALL DETAILS DATE: Thursday, November 6, 2025 TIME: 8:30 a.m. Eastern Time CALL REGISTRATION:https://registrations.events/direct/Q4I91416498WEBCAST:https://events.q4inc.com/attendee/875765587 (available for three months) Advance call registration Participants must register in advance for the live call. After registering, instructions on how to join the call will automatically be emailed, including dial-in informa

HCLTech, a leading global technology company, and Zscaler™, a leader in cloud security, announced the expansion of their strategic partnership to provide AI-powered network transformation and enhanced zero-trust security services to enterprises worldwide. Under the new partnership scope, Zscaler's Zero Trust Exchange™ platform has been integrated with HCLTech's Cybersecurity Fusion Center (CSFC) platform. HCLTech’s AI capabilities, including SecOps and Responsible AI guardrails within HCLTech AI Force and AI Foundry are key to this partnership. This collaboration aims to enhance enterprise resilience and achieve business outcomes with a cloud-first, scalable security solution. HCLTech's Universal Managed Detection and Response (UMDR) services now integrate with Zscaler Internet Access™ (ZIA™), Zscaler Private Access™ (ZPA™) and other Zscaler components, providing context-rich threat detection, advanced analytics and faster response powered by AI and automation. Other key highlights of

Beyon Cyber, part of the Beyon Group and the fastest growing cyber security company in the Middle East, has signed a Memorandum of Understanding (MoU) with Haven Cyber Technologies, a global cyber security services provider and a Microsoft Solutions Partner, through its UK-based subsidiary ITC Secure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016047852/en/ Beyon Cyber and Haven Sign MoU Under the MoU, Beyon Cyber and Haven will form a strategic partnership to revolutionize cyber security operations through the launch of advanced AI-driven Security Operations Centers (AI SOCs) in the United Kingdom and worldwide. As part of this collaboration, Haven will integrate Beyon Cyber’s cutting-edge AI SOC platform, Orryx AI, into its operations; harnessing the power of smart automation and agentic AI workflows to enhance threat detection, investigation, hunting, intelligence, and response. This partnership will enable both or

Information Services Group (ISG) has honored Stefanini at the Women in Digital Awards in EMEA, celebrating Natalia Chiritescu. Chiritescu, Digital Solutions Center (DSC) Director for EMEA, NA, & APAC, was awarded “Bronze Luminary” in the AI Champion category recognizing AI adoption and enablement impact. The ISG Women in Digital Awards program, launched in the Americas in 2022, was expanded in 2023 to the Europe, Middle East and Africa (EMEA) and Asia Pacific regions, including India. In 2025, the global program had a total of 536 finalists and winners were announced on September. “The Women in Digital Awards aim to elevate and connect visionary women across the tech landscape. Natalia Chiritescu’s achievement is a testament to the program’s purpose: to foster collaboration, innovation, and diversity, empowering leaders to drive AI-enabled transformation worldwide,” said Kimberly Tobias, Partner and Leader of ISG Women in Digital. “Being named an AI Champion by ISG is an honor I share

CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced it has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Privileged Access Management1. Recognized as a Leader for the seventh consecutive time, CyberArk is positioned furthest in Completeness of Vision which, from the company's standpoint, reflects CyberArk's commitment to defining the future of privilege access management (PAM), where every identity is protected with flexible as-needed access, smart AI-driven privilege controls, and unified security across both cloud and on-premises systems. The report evaluates tools that manage privileged access for both humans and machines. The CyberArk Identity Security Platform enables organizations to secure all identities – human, machine and AI – with the right level of privilege controls from a single, unified platform. As part of this platform, CyberArk's Privileged Access Management solutions help security teams secure privileged credentials, secret

HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new ownership group and included additional investors Thiel Bio and Founders Fund, among others. The financing will support the ongoing commercial expansion of HistoSonics’ Edison System into new global markets, accelerate new clinical indications throughout the body, and strengthen operational capacity for the next phase of growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016119331/en/ HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics This funding follows the recent $2.25 billion majority stake acquisition of HistoSonics by a consortium of international technology and life science investors, including K5 Global, Bezos Expeditions, and Wellington Management, who all participated in the new round that po

The Estée Lauder Companies Inc. (NYSE:EL), today celebrated the sixtieth anniversary of its Manufacturing & Fulfillment Campus in Oevel, Belgium. Since its opening in 1965, the Oevel Campus has developed into a state-of-the-art manufacturing, fulfillment and biotech hub. Today the campus serves as a cornerstone of the company’s global value chain and is one of its largest manufacturing facilities by volume, annually producing over 100 million prestige beauty products, which are then shipped to more than 100 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016330616/en/ The Estée Lauder Companies celebrates 60th anniversary of its Manufacturing & Fulfillment Campus in Oevel, Belgium “Nearly sixty years ago, my grandparents, Estée and Joseph Lauder, laid the cornerstone of our first facility here in Oevel, establishing what would become a vital part of our global operations,” said William P. Lauder, Chair, Board of